Novartis hatches plans for $16bn bond getaway to avoid costly loan fees
Loans bankers spent much of 2009 hoping for a spurt of M&A activity to reinvigorate the bank debt market but Novartis, announcing the first big deal of 2010 this week, looks likely to arrange what financing it needs in the bond market instead.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ European securitization issuance database
- ✔ Daily newsletters across markets and asset classes
- ✔ 1 weekly securitization podcast
